V1RH12 Inhibitors
V1RH12 inhibitors encompass a variety of chemical compounds that directly or indirectly impede the functional activity of V1RH12 through specific signaling pathways or biological processes. For instance, Wortmannin and LY294002, both phosphoinositide 3-kinase (PI3K) inhibitors, directly thwart the PI3K/AKT signaling pathway, a critical route for V1RH12 activity. By impeding PI3K, these inhibitors prevent subsequent AKT phosphorylation, which is essential for V1RH12 signaling, thus leading to a dampened functional state of V1RH12. Similarly, Rapamycin, an mTOR inhibitor, disrupts the mTORC1 complex and affects downstream signaling pathways that indirectly regulate V1RH12 activity, particularly in the context of cellular growth and metabolism. PD98059 and U0126 are both selective inhibitors of the mitogen-activated protein kinase kinase (MEK), which in turn prevents activation of extrextracellular signal-regulated kinase (ERK), a potential modulator of V1RH12 signaling. Inhibition of this pathway by these compounds can lead to a decrease in V1RH12 activity if it is dependent on the MAPK/ERK pathway. SB203580, which selectively inhibits p38 MAP kinase, also contributes to the downregulation of V1RH12 activity when p38 MAPK-dependent signaling processes are involved.
Furthermore, Dasatinib and Imatinib, as tyrosine kinase inhibitors, have the potential to indirectly inhibit V1RH12 by targeting Src family kinases and several other tyrosine kinases like BCR-ABL, c-Kit, and PDGFR, which might be upstream regulators of V1RH12. Gefitinib, which inhibits EGFR tyrosine kinase, could reduce V1RH12 activity if there is a dependence on EGFR signaling. Sorafenib, with its multi-kinase inhibition profile, and Leflunomide, through its impact on nucleotide synthesis, represent additional means by which the activity of V1RH12 can be indirectly diminished. These inhibitors collectively target different nodes within the signaling networks that govern the functional state of V1RH12, offering diverse approaches to reduce its activity through modulation of specific biochemical pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent phosphoinositide 3-kinase (PI3K) inhibitor. Since V1RH12 is involved in the PI3K signaling pathway, inhibition of PI3K by Wortmannin leads to a decrease in AKT phosphorylation, thereby reducing V1RH12 signaling activities that depend on this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3Ks. LY294002 binds to the ATP-binding site of PI3K, leading to the suppression of the PI3K/AKT signaling pathway, which is crucial for the activity of V1RH12. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that disrupts the mTORC1 complex, affecting downstream signaling pathways, including those that may regulate V1RH12 activity indirectly through cellular growth and metabolism controls. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress and inflammation signaling pathways. By inhibiting JNK, SP600125 can indirectly reduce the functional activity of V1RH12 if it is regulated by JNK-mediated signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of mitogen-activated protein kinase kinase (MEK), which prevents the activation of extracellular signal-regulated kinase (ERK). This can lead to a reduction in V1RH12 activity if V1RH12 is downstream of the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A pyridinyl imidazole compound that selectively inhibits p38 MAP kinase. By hindering p38 MAPK, SB203580 can decrease V1RH12 activity if it is modulated by p38 MAPK-dependent signaling processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A non-competitive inhibitor of MEK1/2, it prevents the activation of ERK1/2. U0126 thereby can decrease V1RH12 activity if V1RH12 signaling is reliant on the MEK/ERK axis for functional activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that can block multiple tyrosine kinases, including Src family kinases. Dasatinib may indirectly inhibit V1RH12 if its activity is associated with Src kinase-dependent pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. If V1RH12 activity is linked to EGFR signaling, Gefitinib could lead to the inhibition of V1RH12 activity by blocking EGFR tyrosine kinase activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A selective inhibitor of several tyrosine kinases, including BCR-ABL, c-Kit, and PDGFR. By inhibiting these kinases, Imatinib could indirectly reduce V1RH12 activity if it is regulated by any of these or related tyrosine kinase pathways. | ||||||